Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
Merck Vs. GSK: The Game-Changer Race In Pharma Excellence
12:14pm, Friday, 22'nd Sep 2023
Despite the increasing number of emerging challenges for the pharmaceutical industry, the management teams at GSK and Merck are successfully coping with them. GSK's revenue was $9.12 billion in the se
3 Reasons to Buy Merck Stock
09:00am, Friday, 22'nd Sep 2023
Merck's crown jewel still sparkles, and that should continue for several years. The drugmaker is on the verge of earning approval for another blockbuster medicine.
Merck and Eisai say two lung-cancer trials failed to meet their main goals
07:31am, Friday, 22'nd Sep 2023
Merck and Japanese partner Eisai said Friday that two late-stage trials of a treatment for a certain type of non-small lung cancer failed to meet their primary goals in a disappointing outcome, but sa
Drugmaker Merck says Keytruda combination fails in lung cancer trial
07:09am, Friday, 22'nd Sep 2023
Merck said on Friday its cancer immunotherapy Keytruda in combination with partner Eisai's drug failed to meet main goals in a late-stage study evaluating it as a treatment for patients with a type of
Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag
09:46am, Thursday, 21'st Sep 2023
The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of cervical cancer disease.
Frontier portfolio company signs collaboration deal with Merck
04:01am, Thursday, 21'st Sep 2023
Frontier IP Group PLC (AIM:FIPP), a firm specialising in the commercialisation of intellectual property, announced in an RNS today that its portfolio company Exscientia has entered into a collaboratio
Exscientia: Merck Deal Further Cements Industry Positioning, Reiterate Buy
02:02pm, Wednesday, 20'th Sep 2023
Exscientia plc has partnered with Merck KGaA for AI-powered drug discovery in complex disease segments, solidifying its industry positioning. AI is gaining traction in the healthcare industry, with pr
Merck: A Blue-Chip Dividend Stock Worth Buying
12:14pm, Wednesday, 20'th Sep 2023
Merck & Co., Inc.'s payout ratios suggest that the market-beating dividend is well-covered. The company's stacked portfolio of therapies and candidates should lead to solid growth moving forward. My i
FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
12:02pm, Wednesday, 20'th Sep 2023
The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved statistically significant and clinically meaningful improvement in progression-free survival.
Flee to Healthcare Stocks if Recession Rears its Head?
07:04am, Wednesday, 20'th Sep 2023
If you're looking for a sector that's on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.
Merck: Secure A Safe 8% Annualized Return For The Next Decade
04:13am, Wednesday, 20'th Sep 2023
Merck's strong performance in the past two years, driven by Keytruda and Lagevrio, has outperformed the market by an impressive 52%. MRK's acquisition of Prometheus Biosciences signals its effort to d
Merck (MRK) Gets CHMP Nod for Keytruda in Adjuvant Lung Cancer
09:47am, Monday, 18'th Sep 2023
Merck's (MRK) Keytruda gets a positive CHMP opinion, recommending the approval of the drug for the adjuvant treatment of adults with non-small cell lung cancer, who are at high risk of recurrence, in
Merck's (MRK) Ebola Vaccine Gets Approval for Kids in Europe
08:17pm, Friday, 08'th Sep 2023
The European Commission approves Merck's (MRK) Ebola vaccine for use in children as young as one year.
4 Factor Dividend Growth Portfolio - Closing In On A Historic First Year
03:20pm, Thursday, 07'th Sep 2023
The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF, with a few minor twists. The portfolio fell by 0.57% in August, outp
Merck & Co., Inc. (MRK) Citi 18th Annual BioPharma Conference (Transcript)
06:40pm, Wednesday, 06'th Sep 2023
Merck & Co., Inc. (NYSE:MRK ) Citi 18th Annual BioPharma Conference September 6, 2023 1:50 PM ET Company Participants Marjorie Green - SVP and Head of Late Stage Oncology, Global Clinical Development
